PRPH and cancer: Moreover, at the multi-cancer level, known cancer drivers such as CDC45 and NUF2 were identified to be involved in edgetic gains while NTRK1, PRPH and MYOC were determined to be involved in edgetic losses and may serve as targets for widely applicable therapeutic interventions.